Zantac’s Developer Settles Lawsuits Claiming Cancer Link

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp



GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Never miss any important news. Subscribe to our newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *